As previous studies had demonstrated that RIG-I stimulation induces immunogenic cell death in human cancer cells [6–8], we asked whether RIG-I-mediated activation of innate immunity would restore the inflammatory phenotype of HPV+ cancer cells, making these cells more sensitive to anticancer therapy. Here, RIGI is linked to cancer.